Virtus Investment Advisers Q2 2026 Portfolio Activity Analysis
This analysis details observable portfolio changes by Virtus Investment Advisers during the second quarter of 2026, highlighting significant stock purchases and sales based on disclosed holdings data.
As part of its investment strategy oversight for Q2 2026 (ending June 30th), Virtus Investment Advisers managed substantial portfolio activity. The firm's insider database reveals specific changes in stock holdings, including both additions and reductions.
The investor noted significant purchases during the quarter. Notable buys included Marvell Technology (MRVL), which saw a portfolio percentage allocation increase from 0% to 0.79%, indicating a new position was established or significantly increased. Similarly, Datadog (DDOG) experienced an increase in its holding count and portfolio percentage allocation rose from 0% to 0.82%. Other significant additions were observed in companies like Broadcom Inc., Western Digital, and KLA Corporation.
Conversely, Virtus also recorded substantial sales during Q2 2026. The most significant sale was of its entire position in Vertex Pharmaceuticals, which completely exited the holding and resulted in a portfolio percentage allocation drop to 0%. Other notable exits included Sirnaomics (SIGNIFICANT_SELL_SYMBOLS). Additionally, there were large reductions in holdings of other stocks like ImmunityBio, where the position was decreased by 54.22%, and EQRx Inc..
These changes reflect a dynamic portfolio management approach focused on specific investment opportunities within certain sectors. Virtus significantly increased its exposure to the Technology sector through acquisitions like MU, DDOG, and AMD. The firm also bolstered positions in Healthcare stocks such as Geron, Verastem, and Precigen. Furthermore, the Energy sector saw notable additions with Devon Energy.
Simultaneously, Virtus reduced its footprint in other areas. The firm divested from Healthcare stocks like Vertex and EQRx, while also decreasing positions significantly in companies such as Broadcom, despite it being a significant buy overall (though the data shows GLW was sold completely). These actions suggest a rebalancing effort or strategic shift away from certain sectors.
The portfolio's holdings count increased to 419, indicating active turnover. The top five holdings by weight accounted for only 4.07% of the total portfolio value (as per portfolio_indicators). This filing shows Virtus made several large transactions during Q2 2026, impacting its overall sector allocation and specific stock positions significantly.